Adjuvant chemotherapy for intrahepatic cholangiocarcinoma: far from a clinical consensus.
作者信息
Qu Wei-Feng, Liu Wei-Ren, Shi Ying-Hong
机构信息
Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of the Ministry of Education, Shanghai, China.
出版信息
Hepatobiliary Surg Nutr. 2021 Dec;10(6):887-889. doi: 10.21037/hbsn-21-362.
Abstract
摘要
相似文献
1
Adjuvant chemotherapy for intrahepatic cholangiocarcinoma: far from a clinical consensus.肝内胆管癌的辅助化疗：远未达成临床共识。
Hepatobiliary Surg Nutr. 2021 Dec;10(6):887-889. doi: 10.21037/hbsn-21-362.
2
Evaluation of postoperative adjuvant chemotherapy for intrahepatic cholangiocarcinoma patients undergoing R1 and R2 resections.对接受R1和R2切除的肝内胆管癌患者术后辅助化疗的评估。
Asian Pac J Cancer Prev. 2012;13 Suppl:169-74.
3
The role of adjuvant therapy after R0 resection for patients with intrahepatic and perihilar cholangiocarcinomas.R0切除术后辅助治疗在肝内胆管癌和肝门周围胆管癌患者中的作用。
Cancer Chemother Pharmacol. 2017 Jan;79(1):99-106. doi: 10.1007/s00280-016-3206-4. Epub 2016 Dec 7.
4
The effect of adjuvant chemotherapy in resectable cholangiocarcinoma: A meta-analysis and systematic review.辅助化疗对可切除胆管癌的疗效：荟萃分析和系统评价。
Hepatobiliary Pancreat Dis Int. 2019 Apr;18(2):110-116. doi: 10.1016/j.hbpd.2018.11.001. Epub 2018 Nov 14.
5
Postoperative adjuvant therapy following radical resection for intrahepatic cholangiocarcinoma: A multicenter retrospective study.肝内胆管癌根治性切除术后的辅助治疗：一项多中心回顾性研究。
Cancer Med. 2020 Apr;9(8):2674-2685. doi: 10.1002/cam4.2925. Epub 2020 Feb 19.
6
Locoregional recurrence after curative intent resection for intrahepatic cholangiocarcinoma: implications for adjuvant radiotherapy.肝内胆管癌根治性切除术后的局部区域复发：辅助放疗的意义
Clin Transl Oncol. 2015 Oct;17(10):825-9. doi: 10.1007/s12094-015-1312-0. Epub 2015 Jun 4.
7
Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma.肝内胆管癌的全身治疗和辅助治疗
Cancer Control. 2017 Jul-Sep;24(3):1073274817729241. doi: 10.1177/1073274817729241.
8
Adjuvant chemotherapy for intrahepatic cholangiocarcinoma: approaching clinical practice consensus?肝内胆管癌的辅助化疗：达成临床实践共识？
Hepatobiliary Surg Nutr. 2020 Oct;9(5):577-586. doi: 10.21037/hbsn.2019.06.12.
9
Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series.新辅助治疗后局部进展期肝内胆管细胞癌行肝移植治疗：一项前瞻性病例系列研究。
Lancet Gastroenterol Hepatol. 2018 May;3(5):337-348. doi: 10.1016/S2468-1253(18)30045-1. Epub 2018 Mar 13.
10
Outcomes of adjuvant treatments for resectable intrahepatic cholangiocarcinoma: Chemotherapy alone, sequential chemoradiotherapy, or concurrent chemoradiotherapy.可切除肝内胆管癌辅助治疗的结果：单纯化疗、序贯放化疗或同期放化疗。
Radiother Oncol. 2018 Sep;128(3):575-583. doi: 10.1016/j.radonc.2018.05.011. Epub 2018 May 22.
引用本文的文献
1
Application value of F-FDG PET/CT in soft tissue metastasis of intrahepatic cholangiocarcinoma: a case report and literature review.F-FDG PET/CT在肝内胆管癌软组织转移中的应用价值：一例报告及文献复习
Front Oncol. 2025 Jan 16;14:1474105. doi: 10.3389/fonc.2024.1474105. eCollection 2024.
2
Surgical Aspects of Intrahepatic Cholangiocarcinoma.肝内胆管癌的外科手术相关方面
Cancers (Basel). 2022 Dec 19;14(24):6265. doi: 10.3390/cancers14246265.
3
Liver transplantation for cholangiocarcinoma: exploring a new land.胆管癌的肝移植：探索新领域。
J Gastrointest Oncol. 2022 Oct;13(5):2696-2698. doi: 10.21037/jgo-22-596.
4
Exploring the function of stromal cells in cholangiocarcinoma by three-dimensional bioprinting immune microenvironment model.通过三维生物打印免疫微环境模型探索胆管癌细胞基质细胞的功能。
Front Immunol. 2022 Aug 2;13:941289. doi: 10.3389/fimmu.2022.941289. eCollection 2022.
本文引用的文献
1
Tumor Burden Dictates Prognosis Among Patients Undergoing Resection of Intrahepatic Cholangiocarcinoma: A Tool to Guide Post-Resection Adjuvant Chemotherapy?肿瘤负荷决定肝内胆管癌切除患者的预后：一种指导术后辅助化疗的工具？
Ann Surg Oncol. 2021 Apr;28(4):1970-1978. doi: 10.1245/s10434-020-09393-7. Epub 2020 Dec 1.
2
Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial.卡瑞利珠单抗联合吉西他滨和顺铂（GEMOX）治疗晚期胆道癌患者的单臂、开放标签、II 期临床试验。
J Immunother Cancer. 2020 Nov;8(2). doi: 10.1136/jitc-2020-001240.
3
Adjuvant chemotherapy for intrahepatic cholangiocarcinoma: approaching clinical practice consensus?肝内胆管癌的辅助化疗：达成临床实践共识？
Hepatobiliary Surg Nutr. 2020 Oct;9(5):577-586. doi: 10.21037/hbsn.2019.06.12.
4
Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial.评估纳武利尤单抗联合伊匹木单抗免疫治疗在晚期胆道癌患者中的疗效：一项 2 期非随机临床试验的亚组分析。
JAMA Oncol. 2020 Sep 1;6(9):1405-1409. doi: 10.1001/jamaoncol.2020.2814.
5
A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.纳武利尤单抗治疗晚期难治性胆道癌患者的 2 期多中心研究。
JAMA Oncol. 2020 Jun 1;6(6):888-894. doi: 10.1001/jamaoncol.2020.0930.
6
Number and Station of Lymph Node Metastasis After Curative-intent Resection of Intrahepatic Cholangiocarcinoma Impact Prognosis.肝内胆管细胞癌根治性切除术后淋巴结转移的数量和部位影响预后。
Ann Surg. 2021 Dec 1;274(6):e1187-e1195. doi: 10.1097/SLA.0000000000003788.
7
Systemic therapies for intrahepatic cholangiocarcinoma.肝内胆管细胞癌的系统治疗。
J Hepatol. 2020 Feb;72(2):353-363. doi: 10.1016/j.jhep.2019.10.009.
8
Histopathology-based immunoscore predicts recurrence for intrahepatic cholangiocarcinoma after hepatectomy.基于组织病理学的免疫评分可预测肝内胆管癌切除术后的复发。
Cancer Immunol Immunother. 2019 Aug;68(8):1369-1378. doi: 10.1007/s00262-019-02371-3. Epub 2019 Jul 23.
9
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.卡培他滨对比观察用于可切除胆管癌（BILCAP）：一项随机、对照、多中心、3 期研究。
Lancet Oncol. 2019 May;20(5):663-673. doi: 10.1016/S1470-2045(18)30915-X. Epub 2019 Mar 25.
10
Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study.吉西他滨和奥沙利铂化疗或监测在切除的胆管癌 (PRODIGE 12-ACCORD 18-UNICANCER GI)：一项随机 III 期研究。
J Clin Oncol. 2019 Mar 10;37(8):658-667. doi: 10.1200/JCO.18.00050. Epub 2019 Feb 1.
Zotero 插件